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Els van de Vijver, PhD; David C. Wilson, PhD; Johannes B. Reitsma, PhD; Marjolein Y. Berger, PhD
IMPORTANCE Bloodmarkers and fecal calprotectin are used in the diagnostic workup for
inflammatory bowel disease (IBD) in pediatric patients. Any added diagnostic value of these
laboratory markers remains unclear.
OBJECTIVE To determine whether adding laboratory markers to evaluation of signs and
symptoms improves accuracy when diagnosing pediatric IBD.
DATA SOURCES A literature search of MEDLINE and EMBASE from inception through
September 26, 2016. Studies were identified using indexing terms and free-text words
related to child, target condition IBD, and diagnostic accuracy.
STUDY SELECTION Two reviewers independently selected studies evaluating the diagnostic
accuracy of more than 1 bloodmarker or fecal calprotectin for IBD, confirmed by endoscopy
and histopathology or clinical follow-up, in pediatric patients with chronic gastrointestinal
symptoms. Studies that included healthy controls and/or patients with known IBDwere
excluded.
DATA EXTRACTION AND SYNTHESIS Individual patient data from each eligible studywere
requested from the authors. In addition, 2 reviewers independently assessed quality with
Quality Assessment of Diagnostic Accuracy Studies–2.
MEANOUTCOMES ANDMEASURES Laboratorymarkers were added as a single test to a
basic predictionmodel based on symptoms. Outcomemeasures were improvement of
discrimination by addingmarkers as a single test and improvement of risk classification
of pediatric patients by adding the best marker.
RESULTS Of the 16 eligible studies, authors of 8 studies (n = 1120 patients) provided their
data sets. All bloodmarkers and fecal calprotectin individually significantly improved the
discrimination between pediatric patients with and those without IBD, when added to
evaluation of symptoms. The best marker—fecal calprotectin—improved the area under
the curve of symptoms by 0.26 (95% CI, 0.21-0.31). The second best marker—erythrocyte
sedimentation rate—improved the area under the curve of symptoms by 0.16 (95% CI,
0.11-0.21). When fecal calprotectin was added to themodel, the proportion of patients
without IBD correctly classified as low risk of IBD increased from 33% to 91%. The proportion
of patients with IBD incorrectly classified as low risk of IBD decreased from 16% to 9%.
The proportion of the total number of patients assigned to the intermediate-risk category
decreased from 55% to 6%.
CONCLUSIONS AND RELEVANCE In a hospital setting, fecal calprotectin added themost
diagnostic value to symptoms compared with bloodmarkers. Adding fecal calprotectin to
the diagnostic workup of pediatric patients with symptoms suggestive of IBD considerably
decreased the number of patients in the group in whom challenges in clinical decisionmaking
are most prevalent.
JAMA Pediatr. 2017;171(10):984-991. doi:10.1001/jamapediatrics.2017.1736
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I t is a diagnostic challenge to differentiate between inflam-matory bowel disease (IBD) and functional gastrointesti-nal disorders, such as irritable bowel syndrome, in pediat-
ric patients. Unnecessary invasive diagnostic testing and
endoscopy need to be balanced against the risk of missing or
delaying a diagnosis of IBD. The diagnostic workup of chil-
dren and adolescents with gastrointestinal symptoms starts
with history and physical examination. Endoscopy is needed
to make a definitive diagnosis of IBD, but this is an invasive
andunpleasantprocedure,especially inpediatricpatients.1The
key question, therefore, is whether commonly used blood
markers or fecal calprotectin improve the accuracy of the di-
agnostic workup beyond the findings of history and physical
examination to select children for endoscopy.2 Informationon
whether the tests addvaluewouldhelp the clinician in choos-
ing tests that are most appropriate and correctly interpreting
the results.
A recentmeta-analysis provided anoverviewof the accu-
racy of signs, symptoms, tests, and test combinations for di-
agnosing IBD in pediatric patients presentingwith symptoms
suggestive for IBD in whom a pediatrician could consider
endoscopy.3 Thismeta-analysis was based only on published
data, and itwas thereforenotpossible todetermineanyadded
valueof tests beyondsigns andsymptoms.Moreover, thevari-
ouscombinationsof test resultswereoftenevaluated inasingle
study; thus, limited informationwas available on how robust
these results were.
High-quality evidence to determine any added value of
tests to symptoms can be achieved by using individual pa-
tient data (IPD) from all relevant studies. In the IPD meta-
analysis, we determined the added diagnostic value of com-
monly used blood markers and fecal calprotectin on top of




WesearchedMEDLINEandEMBASE from inceptionuntil Sep-
tember 26, 2016, to identify diagnostic studies that evalu-
ated more than 1 laboratory test for IBD in pediatric patients
with symptoms suggestive of IBD. We updated the literature
searchused in a recently publishedmeta-analysis3 that incor-
porated indexing terms and free-text words related to child,
target condition IBD, anddiagnostic accuracy (eMethods in the
Supplement). In addition,wehandsearched referencesof full-
text articles, reviews, and guidelines on pediatric IBD.1,4-8 No
language restrictions were applied.
Selection Criteria
Two independent reviewers (G.A.H. andY.L.L.) identified and
selected eligible studies. All studies examining the diagnos-
tic accuracy of more than 1 laboratory test (blood markers or
fecal calprotectin) for a diagnosis of IBD were eligible for in-
clusion. Inflammatory bowel disease had to be confirmed or
rejectedbyhistopathologic analysisofbiopsies retrievedaten-
doscopic examination or rejected by the absence of symp-
toms at clinical follow-up. We included studies that evalu-
ated children or adolescents (from birth to 18 years) with
gastrointestinal symptoms suggestive of IBD. We excluded
studies that included healthy controls and/or patients with
known IBD.
IPD Data Set, Data Extraction,
and Quality Assessment
Wecontacted thecorrespondingauthorsof eligible studiesand
invited them to share their data sets. In case of nonresponse,
wesent2 reminderemails. Ifwehadnoresponseafter the third
email, the study was excluded from analysis. From the pub-
lished reports, 2 reviewers (G.A.H. and Y.L.L.) independently
abstracted informationon country, studydesign, setting, and
age. In addition, the following IPD from each included study
were requested: final diagnosis (IBD/no IBD), levels of labora-
tory tests (bloodmarkers [C-reactiveprotein, erythrocyte sedi-
mentation rate, platelet count, albumin, andhemoglobin] and
fecal calprotectin), and, if available, information on the pres-
ence of symptoms (abdominal pain, diarrhea, rectal bleed-
ing, andweight loss). These IPDwere comparedwith thepub-
lished results. Discrepancieswere discussedwith the authors
and corrected.
Two reviewers (G.A.H. and Y.L.L.) independently as-
sessed the risk of bias and concerns for applicability, using
the Quality Assessment of Diagnostic Accuracy Studies–
2 (QUADAS-2) instrument.9 The study of Holtman et al10 was
assessedby2other reviewerswhohadnotparticipated in this
study (P.H. and D.C.W.). The QUADAS-2 instrument consists
of 4 domains: patient selection, index test, reference stan-
dard, and flow and timing. Disagreements between review-
ers were resolved by consensus or, if necessary, by a third
reviewer (M.Y.B.).
Statistical Analysis
Weused a 2-step approach in this IPDmeta-analysis to deter-
mine thediscriminativeabilityof single laboratorymarkersand
anyaddedvalue to symptoms. In the first step, the resultswere
calculated in each of the studies. In the second step, the re-
sults were meta-analyzed.
Key Points
Question Is there added diagnostic value of bloodmarkers and
fecal calprotectin beyond signs and symptoms for inflammatory
bowel disease in symptomatic pediatric patients?
Findings In an individual patient data meta-analysis including
1120 pediatric patients, fecal calprotectin added themost
diagnostic value to symptoms compared with bloodmarkers.
Addition of fecal calprotectin to the diagnostic workup of pediatric
patients with symptoms suggestive of inflammatory bowel disease
considerably decreased the number of patients in the
intermediate risk of inflammatory bowel disease group, in which
challenges in clinical decisionmaking are most prevalent.
Meaning Fecal calprotectin should be recommended for the
triage of pediatric patients with symptoms suggestive of
inflammatory bowel disease.
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Discrimination ofMarkers
In the first step, we determined the discriminative ability of
single laboratorymarkers by calculating the areaunder the re-
ceiver-operating characteristic curve (AUC) with 95% CIs for
eachdata set. In thesecondstep,wecalculated thepooledAUC
with 95% CIs, using the random-effects generic inverse vari-
ance model.11
Added Value ofMarkers
First,wedeveloped a commonbasicmodel of symptoms con-
sidered predictive for IBD (dichotomous dependent vari-
able), using logistic regression analysis in each data set. The
symptoms were abdominal pain, diarrhea, and rectal bleed-
ing. Other signs and symptoms (eg, involuntary weight loss,
perianal lesions, and growth failure) were not included in the
basic model, because these were not available for all studies.
To estimate the added predictive value of single laboratory
markers,weadded these factors as continuousvariables to the
basic symptoms model. The difference in AUC (Δ AUC) with
95% CI between the basic model and the different extended
modelswitha single laboratorymarkerwascalculated for each
data set, using themethod of DeLong.12,13 In the second step,
a pooled estimate and 95% CI of the Δ AUCwas calculated by
the generic inverse variance method, using random-effects
models.11 Moreover, a forest plot was constructed to visual-
ize the AUC and Δ AUC of each data set and the heterogeneity
between data sets.
Improvement in Diagnostic Risk Classification
To provide more insight in how the pediatric patients were
classified by using the basic model and the shift in classifica-
tion after adding the overall best marker, we constructed a
reclassification table. The predicted probability of IBD in all
pediatric patients was calculated in each data set for both
models. We defined 2 threshold probabilities, 1 below which
a pediatrician decides not to perform endoscopy (probability
<35%) and 1 above which a pediatrician decides to perform
endoscopy (probability >60%). Therefore, 3 risk groups were
created: low risk (predicted probabilities <35%), intermedi-
ate risk (predicted probabilities 35%-60%), and high risk
(predicted probabilities >60%) of IBD. The 2 threshold prob-
abilities were used to calculate 2 × 2 tables for the basic
model and basic model with the best marker in each data
set. The sensitivities and specificities in each data set were
pooled with bivariate random-effects models.14 These
pooled sensitivities and specificities and the median preva-
lence of IBD were used to construct a reclassification table of
100 hypothetical pediatric patients with 3 relevant risk
groups of IBD.
Missing Data
If a specific marker was not evaluated in a single study (sys-
tematicallymissingdata), this data setwasnot includedwhen
calculating apooledestimateof thatmarker. If 1 ormoreof the
3 key symptoms was not evaluated in a study, this study was
not included in the evaluation of the added value of the vari-
ous markers. In case of sporadic missing data, we used mul-
tiple imputations (fully condition specification, predictive
mean matching, 20 iterations, and 5 data sets), with the fol-
lowing variables as predictors: all symptoms (if present), all
laboratorymarkers, anddiagnosis.15,16Weused theRubin rule
to calculate the pooled AUC.17
Statistical analyses were performed with IBM SPSS, ver-
sion20.0.0 (IBMCorp), STATA/SE, version 13 (StataCorp), and
SAS, version9.2 (SAS institute). Findingswere considered sig-
nificant at P < .05.
Results
Selection of Studies
Ofthe2974uniquestudies identified fromthe literaturesearch,
16 diagnostic studies were eligible (eFigure in the Supple-
ment). The IPDwerenot obtained from8 studies (n = 1719pa-
tients) because 3 authors did not respond to emails,18-20 the
data were no longer available,21-24 or the author declined to
share data.25 Themedian prevalence of IBD in the 7 excluded
cohort studies was 45% (range, 19%-67%).18-24 One excluded
study used a case-control design in symptomatic pediatric
patients.25 Five of the 8 excluded studies reported on symp-
toms and blood markers,20,21,23-25 2 reported on blood mark-
ers only,18,22 and 1 study discussed blood markers and fecal
calprotectin.19 Two excluded studies were performed in
Europe18,19 and 6 studies were conducted in North
America.20-25 The test characteristics of the laboratorymark-
ers of the available and excluded studies were comparable,3
except for 1 excluded study that showed to be an outlier for
C-reactive protein and platelet count.22
Characteristics and Quality of Included Studies
We were able to obtain the IPD from 8 studies with a total of
1120 pediatric patients, 560 of whom had IBD. Study and pa-
tient characteristics are given in Table 1 and Table 2. Theme-
dianprevalenceof IBD in the 5 cohort studieswas43% (range,
19%-62%).10,26,29,30,32 Fiveof the8 included studieswereper-
formed in European countries,10,26,27,29,32 2 in Australia,28,30
and 1 in North America.31 All studies were performed in re-
ferred childrenor adolescents (hospital setting); 3useda case-
control design in symptomatic pediatric patients.27,28,31 Qual-
ity assessment of all included studies identified risk of bias in
1 or more domain. We had applicability concerns for patient
selection in 1 study.10 eTable 1 in the Supplement presents the
full QUADAS-2, and eTable 2 in the Supplement presents
thesystematicallymissingandsporadicallymissingvalues; the
sporadically missing values were imputed.
Discrimination ofMarkers
The AUC of the markers, except for platelets and hemoglo-
bin,wereheterogeneousacross studies (eTable3 in theSupple-
ment). The pooled AUC of erythrocyte sedimentation rate (8
studies), albumin (5 studies), C-reactive protein (8 studies),
platelets (6 studies), hemoglobin (5 studies), and fecal calpro-
tectin (6 studies)were0.84 (95%CI, 0.82-0.87), 0.82 (95%CI,
0.73-0.90), 0.79 (95% CI, 0.73-0.85), 0.79 (95% CI, 0.75-
0.83), 0.76 (95%CI, 0.71-0.80), and 0.95 (95%CI, 0.93-0.98),
respectively (Figure 1).
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Added Value ofMarkers
In 2 studies, the basic model could not be fitted, because 1 or
moreof thekey symptomswas systematicallymissing (eTable
2 in the Supplement).27,28 The AUC of the basicmodel ranged
from0.65 to 0.77, and the pooled AUC of the basicmodel was
0.70 (95% CI, 0.65-0.75). The Δ AUCs were fairly homoge-
neous across studies (eTable 4 in the Supplement). Pooled Δ
AUCvalues foradditionofbloodtestmarkers to thebasicmodel
of symptomswere0.16 (95%CI,0.11-0.21) forerythrocyte sedi-
mentation rate (5 studies), 0.13 (95% CI, 0.08-0.19) for plate-
lets (4studies),0.13 (95%CI,0.08-0.19) forhemoglobin (4stud-
ies), 0.13 (95%CI, 0.05-0.21) for albumin (3 studies), and0.08
(95%CI,0.04-0.11) forC-reactiveprotein (5 studies) (Figure2).
The improvement inAUCwhenadding fecal calprotectin to the
basicmodel ranged from0.21 to0.29 andwas statistically sig-
nificant in all data sets (P < .05). ThepooledΔAUCof fecal cal-
protectin was 0.26 (95% CI, 0.21-0.31).
Improvement in Diagnostic Risk Classification
The reclassification table of 100 hypothetical pediatric pa-
tients with IBD prevalence of 43% illustrates that adding the
best marker (fecal calprotectin) to the basic model of symp-
toms leads to a decrease in the intermediate-risk group from
55 to 6 pediatric patients (Table 3).
The proportion of pediatric patients without IBD cor-
rectly classified as low risk of IBD increased from 33% to 91%
and patients with IBD incorrectly classified as low risk of IBD
decreased from 16% to9%. Theproportion of IBD cases in the
low-risk group decreased (from 27% to 7%) and increased in
the high-risk group (from 74% to 95%) when fecal calprotec-
tin was added to symptoms in the workup.
Discussion
This IPD meta-analysis, including 1120 referred pediatric pa-
tients with symptoms suggestive of IBD, demonstrated that
all laboratory markers (erythrocyte sedimentation rate,
C-reactive protein, platelets, hemoglobin, albumin, and fecal
calprotectin) as a single test improved the discrimination be-
tween patients with and those without IBD when added to a
model with symptoms alone. The addition of fecal calprotec-
tin to symptoms improved the AUC more than any of the in-
dividual bloodmarkers.Moreover, fecal calprotectin added to
symptoms improved the diagnostic risk classification by de-
creasing thenumber of pediatric patients in the intermediate-
risk group from 55% to 6%. The pediatric patients weremore
often correctly classified in the low- and high-risk groups af-
ter adding fecal calprotectin to the diagnostic process.
The basicmodel in different data sets performedpoorly to
fairly (AUC varied between 0.65 and 0.77). We have to con-
sider that theperformanceofdiscriminationof thebasicmodel
mighthavebeenbetterwhenmore signsandsymptomswould
have been included in themodel. This was not possible, since
the included studies did often not record involuntary weight
loss, growth failure, perianal lesions, family history of IBD, or
extraintestinal symptoms.We found that, in referred sympto-
matic pediatric patients, all laboratory markers added signifi-
cantdiscriminativevalue tosymptomsaloneandhencearepo-
tentiallyofvalue in the triage forendoscopy.Clinical relevance,
however, depends on treatment thresholds and the trade-off
betweentheutilityofamissed (ordelayed)diagnosisof IBDand
an unnecessary endoscopy under full anesthesia. Guidelines
suggestperformingblood tests inpediatricpatientswithsymp-
toms suggestive for IBD.1,8 Because bloodmarkers, such as he-
moglobin and albumin, alsomay have consequences for treat-
ment choices, this recommendationshouldnotbeabandoned.
However, for the triage of pediatric patients for endoscopy, fe-
cal calprotectin showed the highest discriminative perfor-
mance and should be recommended for this purpose, espe-
cially since a normal fecal calprotectin value (<50 μg/g)makes
thediagnosisof IBDunlikely.4,6Bloodtest resultswithintheref-
erence ranges do not rule out an IBD diagnosis.3,33
The results of this study are applicable to clinicians who
evaluate referred pediatric patients for symptoms suggestive
of IBD.Onedisadvantage to the routineuse of fecal calprotec-
tin in clinical practicemight be thedifficulty inobtaining stool
from adolescents. None of the studieswas performed in non-
referred pediatric patients in primary care. The results in re-
ferredpediatric patients arenot generalizable toprimary care,
because differences in patient spectrum and disease severity
can affect the pretest probability and added value of mark-
ers. In only 1 study, 24 of 90 patients were initially assessed
in primary care and referred to specialist care for further di-
agnostic workup.10 More studies in primary care are needed
to determine the added value of markers in this setting.
ComparisonWith Literature
To our knowledge, this is the first meta-analysis using IPD to
investigate the added value of commonly used laboratory
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a Referredmoderate risk: children referred by their primary care physician (either primary care physician or pediatrician) to a pediatrician or pediatric
gastroenterologist for diagnostic workup; referred high risk: children referred by a pediatrician to a pediatric gastroenterologist and endoscopy.
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markers for diagnosing IBD. However, another IPD meta-
analysis concerning fecal calprotectin in referredpediatric pa-
tients with suspected IBD developed an individual risk pre-
diction rule for IBD.7 The prediction rule was based on fecal
calprotectinvalue and theageof the child. TheAUCof thepre-
dictionmodelwas0.92 (95%CI, 0.89-0.94). In daily practice,
signs and symptoms are usedbefore testingwith bloodmark-
ers or fecal calprotectin. Therefore, it is important to ascer-
tain the incremental value of signs and symptoms alongside
laboratory testing. In thepresent IPDmeta-analysis,weevalu-
ated the most commonly used laboratory markers and pro-
vided insight into which tests are appropriate for triage for
endoscopy.
Degraeuweet al7 found in their IPDmeta-analysis that the
AUCof testingwith fecal calprotectinwas0.94 (95%CI, 0.92-
0.95). In the present IPD meta-analysis, the AUC of fecal cal-
protectin was comparable, even though we included differ-
ent studies. Four studies included in the earlier IPD were not
analyzed in thepresent IPD, because 2 includedonly fecal cal-
protectin testing,34,35 1 study includedpediatric patientswith
known IBD,36 and theauthorsof 1 studydidnot respond toour
efforts to contact them.19 In our IPD meta-analysis, we in-
cluded 2 additional studies,10,29 1 of which was published
after the earlier IPD.10
Strengths and Limitations
Of the 16 eligible studies, we were able to obtain data sets
from 8 studies. Therefore, there might be selection bias.
Because the test characteristics of the laboratory markers of
the available and excluded studies were comparable, we
expect that the excluded studies will not have a large effect
on the results.
Themedian andAUCof some laboratory tests varied con-
siderably between the included studies. These heteroge-
neous results might be explained by the different assays that
wereused for the laboratory tests.Moreover, theAUCmayvary
due todifferent designs (cohort or case-control) and thenum-
berandchoiceof the referencestandards (endoscopyor follow-
up). However, the Δ AUCs were more homogeneous than the
AUCs.We chose a 2-step approach, because this is a transpar-
entmethod that takes into account the hierarchical nature of
the data, which means that patients and procedures from 1
studyaremoreconsistent andsimilar toeachother thanacross
different studies.
Dueto theabsenceof theregistrationof symptoms in3data
sets,27,28,31 it was not possible to determine the added value of
themarkers in thesedatasets.Wedidnotask theauthors to ret-
rospectively reviewthesymptoms in themedical records, since
thiswouldmake the information less reliable. Inaddition,only
3 of the 8 studies evaluated all included laboratory markers,
causing a varied number of studies per marker. Another limi-
tation is that thenumberofpatients in the includedstudieswas
Figure 1. Pooled Area Under the Curve (AUC)









CRP 8 0.79 (0.73-0.85)
ESR 8 0.84 (0.82-0.87)
Platelets 6 0.79 (0.75-0.83)
Hb 5 0.76 (0.71-0.80)
Albumin 5 0.82 (0.73-0.90)
FCal 6 0.95 (0.93-0.98)
CRP indicates C-reactive protein; ESR, erythrocyte sedimentation rate;
FCal, fecal calprotectin; and Hb, hemoglobin.
Figure 2. Pooled Improvement in Area Under the Curve (AUC)














CRP 5 0.08 (0.04-0.11)
ESR 5 0.16 (0.11-0.21)
Platelets 4 0.13 (0.08-0.19)
Hb 4 0.13 (0.08-0.19)
Albumin 3 0.13 (0.05-0.21)
FCal 5 0.26 (0.21-0.31)
A Δ AUC value greater than 0 implies an added discriminative value of the
laboratory test, and a value of 0 or less implies no added discriminative value.
CRP indicates C-reactive protein; ESR, erythrocyte sedimentation rate;
FCal, fecal calprotectin; and Hb, hemoglobin.
Table 3. Improved Diagnostic Risk Classification After Adding Fecal Calprotectin to Symptoms
in a Hypothetical Cohort of 100 ChildrenWith IBD Prevalence of 43%a




Low, <35% 7 19 26
Intermediate, 35%-60% 22 33 55
High, >60% 14 5 19
Total risk group 43 57 100
Basic Model Plus Fecal Calprotectin
Low, <35% 4 52 56
Intermediate, 35%-60% 3 3 6
High, >60% 36 2 38
Total risk group 43 57 100
Abbreviation: IBD, inflammatory
bowel disease.
a The numbers are based on the
median prevalence of IBD of 43%
across cohort studies and pooled
sensitivities and specificities of the
basic and the basic plus fecal
calprotectin model at low and high
predicted probabilities of IBD. The
pooled sensitivities for the basic and
basic plus fecal calprotectin model
at low predicted probabilities were
0.84 and 0.91, respectively, and the
pooled specificities were 0.33 and
0.92, respectively. At high predicted
probabilities, the respective pooled
sensitivities were 0.33 and 0.84,
and pooled specificities were 0.92
and 0.96.
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small. Toomanypredictors for a lownumber of patients in the
studiesmaycauseperfectdiscrimination.TheAUCof fecal cal-
protectinwasveryhigh,whichmightbeanoverestimation.Due
to the high AUC of symptoms and fecal calprotectin, there is a
small chance that bloodmarkers could have had added value.
However, thenumberofpediatricpatients in the includedstud-
ies of this IPD meta-analysis was too small to determine the
added value of blood markers to symptoms and fecal calpro-
tectin.Wedidnotcorrect foroveroptimism,becausewedidnot
develop a single clinical prediction rule and the Δ AUC is less
sensitive for overoptimism since both the basicmodel and the
extended model are not corrected. A methodologic study is
needed to provide more insight in the overoptimism of the Δ
AUC. A large studywithmore patientswith andwithout IBD is
needed todevelop apredictionmodel for IBDbasedonpatient
characteristics, single signsandsymptoms,bloodmarkers, and
fecal calprotectin.Moreover, agewould be important to incor-
porate in the prediction rule, because age influences the prob-
ability of IBD and the fecal calprotectin values.
Since the AUC is an overall measure of discrimination
and gives no insight to clinical interpretation, we provided a
reclassification table of the best marker as an illustration of
the potential impact of adding a marker to the basic model.
We assume that, when referred patients are classified into the
low-risk group (probability <35%), the pediatrician decides
not to perform an endoscopy, while patients in the high-risk
group (probability >60%) are considered likely to have IBD
and require an endoscopy to determine the diagnosis. The
choice of thresholds and the resulting risk groups may be
debated, because the thresholds could be variable among, for
example, clinicians and regions. Other thresholds to define
the 3 risk groups could change the reclassifications. However,
35% and 60% are reasonable thresholds in specialist care,
because studies show that pediatric patients with a probabil-
ity for IBD of approximately 35% are referred to the pediatric
gastroenterologist and pediatric patients with a probability of
approximately 60% received an endoscopy.32,37 For the clini-
cian, the intermediate-risk group is the most challenging,
because uncertainty about appropriate management is high-
est. Nevertheless, uncertainty about diagnosis remains in all
risk categories, and children and parents should be informed
about this.
Conclusions
In referredpediatricpatients, fecal calprotectinaddedthemost
diagnostic value to symptomscomparedwith commonlyused
blood markers. Addition of fecal calprotectin to the diagnos-
tic workup of referred pediatric patients with symptoms
suggestive of IBD considerably decreased the number of
pediatric patients in the intermediate-risk for IBD group.
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